Ethical considerations of cellular immunotherapy for cancer

被引：9
作者：
Ren, Sang-sang [1 ]
Deng, Jing-wen [2 ]
Hong, Meng [2 ]
Ren, Yan-li [2 ]
Fu, Hai-jing [2 ]
Liu, Yan-ning [2 ]
Chen, Zhi [1 ,2 ]
机构：
[1] Zhejiang Univ, Sch Med, Dept Publ Hlth, Hlth Policy & Hosp Management Res Ctr, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis, Sch Med,Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
来源：
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B | 2019年 / 20卷 / 01期
关键词：
Cancer; Cellular immunotherapy; Ethical issue; NATURAL-KILLER-CELL; T-CELLS; DENDRITIC CELLS; TUMOR; RECEPTORS; CHEMOTHERAPY; NEOANTIGENS; VACCINATION; EXPRESSION; LYMPHOMA;
D O I：
10.1631/jzus.B1800421
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
With the rapid development of immunology, molecular biology, and associated technologies such as next-generation sequencing, cellular immunotherapy has recently become the fourth major cancer treatment. Immunotherapies based on T cells, natural killer cells, and dendritic cells play key roles in cancer immunotherapy. However, their application in clinical practice raises several ethical issues. Thus, studies should focus on proper adherence to basic ethical principles that can effectively guide and solve related clinical problems in the course of treatment, improve treatment effects, and protect the rights and interests of patients. In this review, we discuss cellular immunotherapy-related ethical issues and highlight the ethical practices and current status of cellular immunotherapy in China. These considerations may supplement existing ethical standards in cancer immunotherapy.
引用
收藏
页码：23 / 31
页数：9
相关论文
共 36 条
[1]   IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor [J].
Adachi, Keishi ;
Kano, Yosuke ;
Nagai, Tomohiko ;
Okuyama, Namiko ;
Sakoda, Yukimi ;
Tamada, Koji .
NATURE BIOTECHNOLOGY, 2018, 36 (04) :346-+
[2]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[3]   Clinical use of dendritic cells for cancer therapy [J].
Anguille, Sebastien ;
Smits, Evelien L. ;
Lion, Eva ;
van Tendeloo, Viggo F. ;
Berneman, Zwi N. .
LANCET ONCOLOGY, 2014, 15 (07) :E257-E267
[4]   The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Mishra, Anjali ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Becknell, Brian ;
Baiocchi, Robert A. ;
Zhang, Jianying ;
Yu, Jianhua ;
Smith, Megan K. ;
Greenfield, Carli N. ;
Porcu, Pierluigi ;
Devine, Steven M. ;
Rotem-Yehudar, Rinat ;
Lozanski, Gerard ;
Byrd, John C. ;
Caligiuri, Michael A. .
BLOOD, 2010, 116 (13) :2286-2294
[5]   NK cell-based immunotherapy for malignant diseases [J].
Cheng, Min ;
Chen, Yongyan ;
Xiao, Weihua ;
Sun, Rui ;
Tian, Zhigang .
CELLULAR & MOLECULAR IMMUNOLOGY, 2013, 10 (03) :230-252
[6]   Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens [J].
Childs, Richard W. ;
Carlsten, Mattias .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (07) :487-498
[7]  
Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432
[8]   Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma [J].
Fukuda, Keitaro ;
Funakoshi, Takeru ;
Sakurai, Toshiharu ;
Nakamura, Yoshio ;
Mori, Mariko ;
Tanese, Keiji ;
Tanikawa, Akiko ;
Taguchi, Junichi ;
Fujita, Tomonobu ;
Okamoto, Masato ;
Amagai, Masayuki ;
Kawakami, Yutaka .
MELANOMA RESEARCH, 2017, 27 (04) :326-334
[9]   Advantages and applications of CAR-expressing natural killer cells [J].
Glienke, Wolfgang ;
Esser, Ruth ;
Priesner, Christoph ;
Suerth, Julia D. ;
Schambach, Axel ;
Wels, Winfried S. ;
Grez, Manuel ;
Kloess, Stephan ;
Arseniev, Lubomir ;
Koehl, Ulrike .
FRONTIERS IN PHARMACOLOGY, 2015, 6
[10]   EXPRESSION OF IMMUNOGLOBULIN-T-CELL RECEPTOR CHIMERIC MOLECULES AS FUNCTIONAL RECEPTORS WITH ANTIBODY-TYPE SPECIFICITY [J].
GROSS, G ;
WAKS, T ;
ESHHAR, Z .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (24) :10024-10028
1234